Core Insights - Lisata Therapeutics is advancing its development portfolio centered around its product candidate, certepetide, with promising preliminary Phase 2b data for pancreatic cancer and multiple upcoming milestones expected over the next 12+ months [1][3][4] Development Portfolio Highlights - Certepetide is designed to enhance the delivery of anti-cancer agents to solid tumors and has shown favorable safety and clinical activity in trials [4][18] - The ASCEND trial, a Phase 2b study, has completed enrollment with 95 patients, showing a positive trend in overall survival and four complete responses in the treatment group [4][6] - Cohort B data from the ASCEND trial is anticipated in the coming months, with a total of 63 patients involved [4][5] - Other ongoing trials include BOLSTER for cholangiocarcinoma, CENDIFOX for pancreatic and colon cancers, and iLSTA for non-resectable pancreatic cancer, with data expected in mid-2025 [6][10][12] Financial Highlights - For the year ended December 31, 2024, Lisata reported revenue of $1.0 million, a decrease in operating expenses to $23.4 million from $25.7 million in 2023, and a net loss of $20.0 million [9][10][12] - Research and development expenses decreased to approximately $11.3 million, while general and administrative expenses were approximately $12.1 million [10][11] - As of December 31, 2024, the company had cash and marketable securities of approximately $31.2 million, which is expected to support operations into the second quarter of 2026 [13][18] Collaborations and Agreements - Lisata has entered into a collaboration with Kuva Labs to explore the use of certepetide in conjunction with imaging technology, receiving a $1.0 million upfront license fee and potential milestone payments [8][9] - The company is also collaborating with the University of Cincinnati and Valo Therapeutics for various studies involving certepetide [6][7]

Group 1 - Lisata Therapeutics, Inc. will report its financial results for the twelve months ended December 31, 2024, on February 27, 2025, after market close [1] - A conference call will be hosted at 4:30 p.m. Eastern time on the same day, with registration required for participation [2] - A live webcast of the call will be available on Lisata's website and will be accessible for replay for 12 months after the call [3] Group 2 - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and other serious diseases, with its lead product candidate, certepetide, designed to enhance the targeting of anti-cancer drugs [4] - The company has established significant commercial and R&D partnerships based on its CendR Platform® technology and anticipates announcing multiple milestones over the next 1.5 years [4] - Lisata expects its projected capital to fund operations into the second quarter of 2026, covering anticipated data milestones from ongoing and planned clinical trials [4]

BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New Yor ...

Core Viewpoint - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, with a corporate overview presentation scheduled at the 2025 BIO CEO & Investor Conference [1][2]. Company Overview - Lisata Therapeutics is dedicated to the discovery, development, and commercialization of therapies targeting advanced solid tumors and major diseases [3]. - The company's investigational drug, certepetide, is designed to activate a novel uptake pathway for more effective targeting and penetration of solid tumors by anti-cancer drugs [3]. - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3]. - The company anticipates announcing numerous milestones over the next 1.5 years and believes its projected capital will fund operations into early 2026, including data milestones from ongoing and planned clinical trials [3].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented at the 2025 ASCO Gastrointestinal Cancers Symposium BASKING RIDGE, N.J. and SUBIACO, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious disease ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Data reported positive trend in overall survival, including 4 complete responses observed in the certepetide treatment group compared to none in placebo group Data from Cohort B expected in the coming months, with full data from both cohorts to be reported thereafter BASKING RIDGE, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or ...

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company is working on its investigational drug candidate, certepetide, which utilizes a novel uptake pathway to enhance the targeting and penetration of anti-cancer drugs in solid tumors [3] Upcoming Event - David J. Mazzo, PhD, President and CEO of Lisata, will present a corporate overview at the Sequire Investor Summit scheduled for January 21-23, 2025, in San Juan, Puerto Rico [1][2] - The presentation is set for January 22 at 10:00 a.m. Atlantic Standard Time [2] Financial and Operational Outlook - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3] - The company anticipates announcing multiple milestones over the next 1.5 years and projects that its capital will support operations into early 2026, including data milestones from ongoing and planned clinical trials [3]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...